Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CRO ShangPharma Plans $90 Million IPO on the NYSE

publication date: Oct 4, 2010
ShangPharma Corp., the Shanghai-based CRO, announced plans to stage a $90 million IPO on the New York Stock Exchange. Founded in 2003, the company is one of the largest CROs in China with a staff of more than 1,600 scientists. One of its six divisions, Shanghai ChemPartner, is devoted exclusively to projects from Eli Lilly Company. More details....

Stock Symbol: (NYSE: LLY)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital